BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 32201514)

  • 1. A novel classification based on B-cell receptor signal gene expression correlates with prognosis in primary breast diffuse large B-cell lymphoma.
    Su W; Niu X; Ji H; Xu Y; Zhong L; Wang S; Tang D; Zhou X; Zhang Q; Zhou J
    J Cancer; 2020; 11(9):2431-2441. PubMed ID: 32201514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center.
    Li X; Xu-Monette ZY; Yi S; Dabaja BS; Manyam GC; Westin J; Fowler N; Miranda RN; Zhang M; Ferry JA; Medeiros LJ; Harris NL; Young KH
    Am J Surg Pathol; 2017 Oct; 41(10):1309-1321. PubMed ID: 28817403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.
    Davis RE; Brown KD; Siebenlist U; Staudt LM
    J Exp Med; 2001 Dec; 194(12):1861-74. PubMed ID: 11748286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
    Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
    Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system.
    Akhter A; Masir N; Elyamany G; Phang KC; Mahe E; Al-Zahrani AM; Shabani-Rad MT; Stewart DA; Mansoor A
    J Neurooncol; 2015 Jan; 121(2):289-96. PubMed ID: 25391967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma.
    Dunleavy K; Erdmann T; Lenz G
    Cancer Treat Rev; 2018 Apr; 65():41-46. PubMed ID: 29549872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A reassessment of primary thyroid lymphoma: high-grade MALT-type lymphoma as a distinct subtype of diffuse large B-cell lymphoma.
    Skacel M; Ross CW; Hsi ED
    Histopathology; 2000 Jul; 37(1):10-8. PubMed ID: 10931213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
    Rasmussen PK
    Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colorectal diffuse large B-cell lymphoma: molecular subclassification and prognostic significance of immunoglobulin gene translocation.
    Hori Y; Yamamoto H; Nozaki Y; Torisu T; Fujiwara M; Taguchi K; Nishiyama K; Nakamura S; Kitazono T; Oda Y
    Hum Pathol; 2020 Feb; 96():67-78. PubMed ID: 31734190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL).
    Bavi P; Uddin S; Bu R; Ahmed M; Abubaker J; Balde V; Qadri Z; Ajarim D; Al-Dayel F; Hussain AR; Al-Kuraya KS
    J Pathol; 2011 Jul; 224(3):355-66. PubMed ID: 21506127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
    Camicia R; Winkler HC; Hassa PO
    Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent prognostic factors in diffuse large B-cell lymphoma indicate NF-kappaB pathway as a target for new therapeutic strategies.
    Pavan A; Spina M; Canzonieri V; Sansonno S; Toffoli G; De Re V
    Leuk Lymphoma; 2008 Nov; 49(11):2048-58. PubMed ID: 19021048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYC Protein-positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway.
    Wang WG; Jiang XN; Liu ZB; Zhou XY; Li XQ
    Am J Surg Pathol; 2017 Apr; 41(4):541-549. PubMed ID: 28291124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma.
    Zhang M; Xu-Monette ZY; Li L; Manyam GC; Visco C; Tzankov A; Wang J; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Han van Krieken J; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Piris MA; Medeiros LJ; Pham LV; Young KH
    Aging (Albany NY); 2016 Dec; 8(12):3321-3340. PubMed ID: 27941215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study.
    Marchesi F; Regazzo G; Palombi F; Terrenato I; Sacconi A; Spagnuolo M; Donzelli S; Marino M; Ercolani C; Di Benedetto A; Blandino G; Ciliberto G; Mengarelli A; Rizzo MG
    J Exp Clin Cancer Res; 2018 May; 37(1):95. PubMed ID: 29716630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.
    Xu-Monette ZY; Tu M; Jabbar KJ; Cao X; Tzankov A; Visco C; Nagarajan L; Cai Q; Montes-Moreno S; An Y; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Miranda RN; Medeiros LJ; Young KH
    Oncotarget; 2015 Mar; 6(8):5615-33. PubMed ID: 25760242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.
    Bognar MK; Vincendeau M; Erdmann T; Seeholzer T; Grau M; Linnemann JR; Ruland J; Scheel CH; Lenz P; Ott G; Lenz G; Hauck SM; Krappmann D
    Oncogene; 2016 Aug; 35(32):4269-81. PubMed ID: 26776161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
    Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
    Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.
    Taniguchi K; Takata K; Chuang SS; Miyata-Takata T; Sato Y; Satou A; Hashimoto Y; Tamura M; Nagakita K; Ohnishi N; Noujima-Harada M; Tabata T; Kikuti YY; Maeda Y; Nakamura N; Tanimoto M; Yoshino T
    Am J Surg Pathol; 2016 Mar; 40(3):324-34. PubMed ID: 26752547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression of CCL18 in diffuse large B cell lymphoma and its mechanism research.
    Zhou Q; Huang L; Gu Y; Lu H; Feng Z
    Cancer Biomark; 2018; 21(4):925-934. PubMed ID: 29504526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.